Skip to main content
Log in

Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Bone pain commonly plagues patients with metastatic androgen-independent prostate cancer. Studies of mitoxantrone demonstrated that chemotherapy can substantially reduce this debilitating symptom. Two of the available studies examining the use of docetaxel with and without estramustine for treatment of androgenindependent prostate cancer include a detailed prospective analysis of pain and quality of life. One study required patients to have pain at entry and demonstrated significant improvement in pain. The second study enrolled patients with low prevalence and intensity of pain and did not demonstrate pain relief. The available results, although preliminary, suggest that patients with significant bone pain due to androgen-independent prostate cancer can experience substantial pain relief with docetaxel-based therapy. Larger randomized studies targeting patients with sufficient prevalence and intensity of pain are needed to refine our understanding of the contribution of docetaxel to pain control in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Grossman SA: Assessment of cancer pain: a continuous challenge. Support Care Cancer 1994, 2:105–110.

    Article  CAS  PubMed  Google Scholar 

  2. Li S, Liu J, Zhang H, et al.: Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001, 26:919–922.

    Article  CAS  PubMed  Google Scholar 

  3. Turner SL, Gruenewald S, Spry N, Gebski V: Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001, 84:297–302.

    Article  CAS  PubMed  Google Scholar 

  4. Sandblom G, Carlsson P, Sigsjo P, Varenhorst E: Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001, 85:497–503.

    Article  CAS  PubMed  Google Scholar 

  5. Rhodes DJ, Koshy RC, Waterfield WC, et al.: Feasibility of quantitative pain assessment in outpatient oncology practice. J Clin Oncol 2001, 19:501–508.

    CAS  PubMed  Google Scholar 

  6. Ripamonti C, Fulfaro F: Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 2000, 4:187–196. Thorough and current review of both pathophysiology and treatment of bone pain secondary to metastases.

    CAS  PubMed  Google Scholar 

  7. Foley KM: Pain syndromes in patients with cancer. Med Clin North Am 1987, 71:169–184.

    CAS  PubMed  Google Scholar 

  8. Portenoy RK: Pain and quality of life: clinical issues and implications for research. Oncology (Huntingt) 1990, 4:172–178.

    CAS  Google Scholar 

  9. Helme RD: Chronic pain management in older people. Eur J Pain 2001, 5:31–36.

    Article  PubMed  Google Scholar 

  10. Gloth FM,: Geriatric pain: factors that limit pain relief and increase complications. Geriatrics 2000, 55:46–48. Thorough, yet succinct coverage of pain management and assessment issues in the older adult.

    PubMed  Google Scholar 

  11. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 1982, 50:1913–1918.

    Article  CAS  PubMed  Google Scholar 

  12. Turk DC, Melzack R, eds: Handbook of Pain Assessment, edn 1. New York: Guilford Press; 1992.

    Google Scholar 

  13. Herr HW: Quality of life in prostate cancer patients. CA Cancer J Clin 1997, 47:207–217.

    Article  CAS  PubMed  Google Scholar 

  14. de Wit R, van Dam F, Abu-Saad HH, et al.: Empirical comparison of commonly used measures to evaluate pain treatment in cancer patients with chronic pain. J Clin Oncol 1999, 17:1280.

    PubMed  Google Scholar 

  15. Chibnall JT, Tait RC: Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales. Pain 2001, 92:173–186. Useful review of the issues of symptom assessment in the cognitively impaired older adult.

    Article  CAS  PubMed  Google Scholar 

  16. Melzack R: The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975, 1:277–299.

    Article  CAS  PubMed  Google Scholar 

  17. Hortobagyi GN: Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999, 26:32–36.

    CAS  PubMed  Google Scholar 

  18. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al.: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20:1–15.

    CAS  PubMed  Google Scholar 

  19. Beer TM, Bubalo JS: Complications of chemotherapy for prostate cancer. Semin Urol Oncol 2001, 19:222–230. Review of common toxicities of modern prostate cancer chemotherapy and a compilation of patient-dependent factors that guide safe and appropriate use of antineoplastic therapies in the older patient.

    CAS  PubMed  Google Scholar 

  20. Dawson NA, McLeod DG: The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 1997, 33:560–565.

    Article  CAS  PubMed  Google Scholar 

  21. Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder. Prostate 2000, 45:184–193. Contemporary review of chemotherapy for the treatment of prostate cancer.

    Article  CAS  PubMed  Google Scholar 

  22. Tannock I, Gospodarowicz M, Meakin W, et al.: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989, 7:590–597.

    CAS  PubMed  Google Scholar 

  23. Moore MJ, Osoba D, Murphy K, et al.: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994, 12:689–694.

    CAS  PubMed  Google Scholar 

  24. Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756–1764.

    CAS  PubMed  Google Scholar 

  25. Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365–376.

    Article  CAS  PubMed  Google Scholar 

  26. Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506–2013.

    CAS  PubMed  Google Scholar 

  27. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999, 26(Suppl 17):14–18.

    CAS  PubMed  Google Scholar 

  28. Friedland D, Cohen J, Miller R,, et al.: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999, 26:19–23.

    CAS  PubMed  Google Scholar 

  29. Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001, 28:8–15.

    Article  CAS  PubMed  Google Scholar 

  30. Beer TM, Pierce WC, Lowe BA, Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001, 12:1273–1279. Prospective phase II evaluation of docetaxel in patients with pain due to metastatic prostate cancer.

    Article  CAS  PubMed  Google Scholar 

  31. Osoba D, Zee B, Pater J, et al.: Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian, and lung cancer. Qual Life Res 1994, 3:353–364.

    Article  CAS  PubMed  Google Scholar 

  32. Osoba D, Rodrigues G, Myles J, et al.: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139–144.

    CAS  PubMed  Google Scholar 

  33. Osoba D, Tannock IF, Ernst DS, Neville AJ: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654–1663.

    CAS  PubMed  Google Scholar 

  34. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993, 53:4573–4581.

    CAS  PubMed  Google Scholar 

  35. Stearns ME, Tew KD: Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985, 45:3891–3897.

    CAS  PubMed  Google Scholar 

  36. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992, 52:4433–4440.

    CAS  PubMed  Google Scholar 

  37. Pienta KJ, Naik H, Lehr JE: Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology 1996, 48:164–170.

    Article  CAS  PubMed  Google Scholar 

  38. Petrylak DP, Macarthur R, O’Connor J, et al.: Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999, 26:28–33.

    CAS  PubMed  Google Scholar 

  39. Savarese DM, Halabi S, Hars V, et al.: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001, 19:2509–2516.

    CAS  PubMed  Google Scholar 

  40. Kornblith AB, Herndon JE,, Zuckerman E, et al.: The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001, 12:633–641. Prospective phase II evaluation of pain and QOL in AIPC patients treated with docetaxel and estramustine.

    Article  CAS  PubMed  Google Scholar 

  41. Sinibaldi VJ, Carducci M, Laufer M, Eisenberger M: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999, 26:45–48.

    CAS  PubMed  Google Scholar 

  42. Copur MS, Ledakis P, Lynch J, et al.: Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001, 28:16–21.

    Article  CAS  Google Scholar 

  43. Beer TM, Hough KM, Garzotto M, et al.: Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001, 28:49–55.

    Article  CAS  PubMed  Google Scholar 

  44. Ryan CW, Stadler WM, Vogelzang NJ: Docetaxel and exisulind in hormone-refractory prostate cancer. Semin Oncol 2001, 28:56–61.

    Article  CAS  PubMed  Google Scholar 

  45. Figg WD, Arlen P, Gulley J, et al.: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgenindependent prostate cancer. Semin Oncol 2001, 28:62–66.

    Article  CAS  PubMed  Google Scholar 

  46. Tolcher AW: Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001, 28:67–70.

    Article  CAS  PubMed  Google Scholar 

  47. Small EJ, Bok R, Reese DM, et al.: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgenindependent prostate cancer. Semin Oncol 2001, 28:71–76.

    Article  CAS  PubMed  Google Scholar 

  48. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.

    Article  CAS  PubMed  Google Scholar 

  49. Bubley GJ, Carducci M, Dahut W, et al.: Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461–3467.

    CAS  PubMed  Google Scholar 

  50. Cella DF, Tulsky DS, Gray G, et al.: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570–579.

    CAS  PubMed  Google Scholar 

  51. Esper P, Mo F, Chodak G, et al.: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997, 50:920–928.

    Article  CAS  PubMed  Google Scholar 

  52. Cleeland CS, Syrjala KL: How to assess cancer pain. In Pain Assessment, edn 1. Edited by Turk D, Melzack R. New York: Guilford Press; 1992:360–387.

    Google Scholar 

  53. Daut RL, Cleeland CS, Flanery RC: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983, 17:197–210.

    Article  CAS  PubMed  Google Scholar 

  54. Schipper H, Clinch J, McMurray A, Levitt M: Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984, 2:472–483.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beer, T.M., Bubalo, J.S. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Curr Urol Rep 3, 232–238 (2002). https://doi.org/10.1007/s11934-002-0070-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-002-0070-z

Keywords

Navigation